OBJECTIVE: To determine the variability of serum IgG in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: All 25 CIDP patients had active but stable disease and were treated with individually optimised fixed dose IVIg regimens. IgG was measured by turbidimetry and variability was defined as coefficient of variation (CV). RESULTS: The intra-patient variability of the pre-treatment IgG levels, post-treatment levels and increase in serum IgG shortly after IVIg (ΔIgG) was low (mean CV=3%, 4%, 10%). The inter-patient variability between patients treated with the same dose and interval was low in pre-treatment, post-treatment and ΔIgG level (mean CV=13%, 11%, 20%). The ΔIgG levels were associated with IVIg dosage (rs=0.78, p<0.001). CONCLUSIONS: Clinically stable CIDP patients show a steady-state in serum IgG after serial IVIg infusions. The low intra- and inter-patient variability in IgG may indicate that constant levels are required to reach this stability.
OBJECTIVE: To determine the variability of serum IgG in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: All 25 CIDPpatients had active but stable disease and were treated with individually optimised fixed dose IVIg regimens. IgG was measured by turbidimetry and variability was defined as coefficient of variation (CV). RESULTS: The intra-patient variability of the pre-treatment IgG levels, post-treatment levels and increase in serum IgG shortly after IVIg (ΔIgG) was low (mean CV=3%, 4%, 10%). The inter-patient variability between patients treated with the same dose and interval was low in pre-treatment, post-treatment and ΔIgG level (mean CV=13%, 11%, 20%). The ΔIgG levels were associated with IVIg dosage (rs=0.78, p<0.001). CONCLUSIONS: Clinically stable CIDPpatients show a steady-state in serum IgG after serial IVIg infusions. The low intra- and inter-patient variability in IgG may indicate that constant levels are required to reach this stability.
Authors: Jeffrey A Allen; Mamatha Pasnoor; Mazen M Dimachkie; Senda Ajroud-Driss; Thomas H Brannagan; Albert A Cook; Timothy Walton; Mark B Fiecas; John T Kissel; Ingemar Merkies; Kenneth C Gorson; Richard A Lewis Journal: Neurology Date: 2021-02-16 Impact factor: 9.910
Authors: Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter Journal: Front Immunol Date: 2014-12-12 Impact factor: 7.561